News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Johnson & Johnson (JNJ)-Medivir AB (MVRBF)'s Drug Works Against Hepatitis C



10/22/2013 7:57:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Johnson & Johnson (JNJ)’s and Medivir AB (MVIRB)’s experimental hepatitis C treatment is safe and effective, U.S. regulators said, providing a boost to the companies as they try to reach a highly competitive market for new treatments. The drug known as simeprevir helps cure patients of the infectious disease that can lead to a liver transplant, Food and Drug Administration staff said in a review today ahead of an Oct. 24 meeting of agency advisers to discuss the medicine. The FDA is scheduled to decide whether to approve simeprevir for sale by Nov. 27.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg
Read at Washington Post


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES